Medanta has successfully conducted the maximum number of surgeries using the TAVR procedure in India with 150 surgeries till date. And is one of the leaders in Asia. Like by-pass/CABG, the decision to conduct TAVR rests on each individual case, the stage of the disease and other parameters. It is an option to CABG and not a replacement.
The fact that it has applicability to a larger population as well adds to treatment options and complements cardiology. TAVR is used for the replacement of the aortic valve, one of the four valves of the heart. “Medanta strives to enhance patient access to the best possible treatment system benchmarked to global standards. The healthcare industry is now being driven by patient centric solutions powered by technology.It has resulted in improving patient care and management resulting in better patient engagement and satisfaction. The successful utilisation of the TAVR procedure complements our expertise in CABG and strengthens patient outcomes. It also illustrates our deep commitment to cutting-edge technology and patient-centric clinical excellence,” said Dr. Naresh Trehan, chairman and managing director, Medanta.
